Status:
COMPLETED
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
Lead Sponsor:
Dow University of Health Sciences
Collaborating Sponsors:
Higher Education Commission (Pakistan)
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinica...
Detailed Description
Passive immunization using intravenous immunoglobulins (IVIG) has been tested for treating previous viral outbreaks and holds the potential to save lives in the current crisis. Recently researchers fr...
Eligibility Criteria
Inclusion
- Above 18 years of age
- Have positive SARS-CoV-2 PCR on nasopharyngeal and/or oropharyngeal swabs
- Admitted in isolation ward and ICU of institutes affiliated with DUHS
- have severe or critical COVID 19 as judged by the treating physician
- Consent given by the patient or first degree relative
Exclusion
- Pregnancy
- Previous allergic reaction to immunoglobulin treatment
- Ig A deficiency
- Patient requiring 2 inotropic agents to maintain blood pressures
- Known case of any autoimmune disorder
- Acute kidney injury or chronic renal failure
- Known case of thromboembolic disorder
- Aseptic meningitis
Key Trial Info
Start Date :
June 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04521309
Start Date
June 19 2020
End Date
February 8 2021
Last Update
March 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dow University of Health Sciences
Karachi, Sindh, Pakistan, 74200